Treating individuals 3: from subgroups to individuals: general principles and the example of carotid endarterectomy.
about
Assessing and reporting heterogeneity in treatment effects in clinical trials: a proposalMedical concepts related to individual risk are better explained with "plausibility" rather than "probability"Statistical Methods for Establishing Personalized Treatment Rules in OncologyMultivariable risk prediction can greatly enhance the statistical power of clinical trial subgroup analysisPrognosis research strategy (PROGRESS) 4: stratified medicine researchTime-dependent parameter of perfusion imaging as independent predictor of clinical outcome in symptomatic carotid artery stenosisRisk and treatment effect heterogeneity: re-analysis of individual participant data from 32 large clinical trials.Using group data to treat individuals: understanding heterogeneous treatment effects in the age of precision medicine and patient-centred evidence.New data about stenting versus endarterectomy for symptomatic carotid artery stenosis.Evaluating marker-guided treatment selection strategies.National Stroke Association guidelines for the management of transient ischemic attacks.A risk factor-based predictive model of outcomes in carotid endarterectomy: the National Surgical Quality Improvement Program 2005-2010Random treatment assignment using mathematical equipoise for comparative effectiveness trials.Symptomatic carotid atherosclerotic disease: correlations between plaque composition and ipsilateral stroke risk.Risk factors associated with cerebrovascular recurrence in symptomatic carotid disease: a comparative study of carotid plaque morphology, microemboli assessment and the European Carotid Surgery Trial risk model.Examining the evidence: a systematic review of the inclusion and analysis of older adults in randomized controlled trialsThe Risk of Paradoxical Embolism (RoPE) Study: developing risk models for application to ongoing randomized trials of percutaneous patent foramen ovale closure for cryptogenic stroke.Between-centre differences and treatment effects in randomized controlled trials: a case study in traumatic brain injuryDetecting treatment-covariate interactions using permutation methods.Development and validation of a simplified Stroke-Thrombolytic Predictive Instrument.A new taxonomy for stakeholder engagement in patient-centered outcomes research.Performance of models for estimating absolute risk difference in multicenter trials with binary outcome.Implications of Heterogeneity of Treatment Effect for Reporting and Analysis of Randomized Trials in Critical CarePrevention of stroke in patients with diabetes mellitus and the metabolic syndrome.Economic inequalities in the effectiveness of a primary care intervention for depression and suicidal ideationSymptomatic and asymptomatic carotid stenosis: how, when, and who to treat?Competing risk and heterogeneity of treatment effect in clinical trials.Peculiarities of stroke risk in women.Current status of carotid endarterectomy and stenting for symptomatic carotid stenosis.A predictive enrichment procedure to identify potential responders to a new therapy for randomized, comparative controlled clinical studiesPerspectives from the clinic: will the average physician embrace personalized medicine?Dealing with heterogeneity of treatment effects: is the literature up to the challenge?Using internally developed risk models to assess heterogeneity in treatment effects in clinical trialsRethinking trial strategies for stroke and patent foramen ovaleA comprehensive review of predictive and prognostic composite factors implicated in the heterogeneity of treatment response and outcome across disease areas.Predictive and prognostic factors influencing outcomes of rituximab therapy in systemic lupus erythematosus (SLE): A systematic review.Preliminary experience with MRA in evaluating the degree of carotid stenosis and plaque morphology using high-resolution sequences after gadofosveset trisodium (Vasovist) administration: comparison with CTA and DSA.Estimates of absolute treatment benefit for individual patients required careful modeling of statistical interactions.Against pragmatism: on efficacy, effectiveness and the real world.Patent foramen ovale in cryptogenic stroke: incidental or pathogenic?
P2860
Q24288920-B8017F71-D771-48CB-9D38-3EDC7353B22AQ24814919-697B72EA-1457-46A0-B7CA-CB638F16D379Q26786366-B6594503-FB70-438A-9D58-06F7A02C812FQ28196553-26F51E78-86C1-41DF-B038-F99DD498D484Q28709167-137F74BF-B34E-4B0E-9B7B-9656E81648A6Q30385392-AF58616D-D836-42E4-8606-9218A0C5463AQ31112168-CA9899E7-A8AF-4582-804F-A7DBBA212A85Q31143342-98C08897-9BF7-4FF4-AF73-DDD9D44E2C81Q33443582-0992579D-F5BD-435B-82D6-539B02F9DEA6Q34422281-206E9293-AF55-4002-9A60-4BB799578C7AQ34557865-B5A6BACF-A4D2-4E93-B217-6E6BB322B93FQ34785996-C2EA9139-D344-4794-8C41-DA8E1FE39990Q34794180-04191A6A-E124-4AB9-A7FB-FC37E116F38FQ34848415-6457C905-89BC-4663-982C-D0A43DBA7C74Q35021729-4A1DA044-7C47-48A5-B612-FFDCBD57874BQ35111965-BC615E32-BD62-4AC0-8397-C2A8118337CAQ35206129-58E8CAA4-359D-4732-9926-5BEE6618C8E8Q35206136-AD0DE99A-025A-4899-9F05-4A6E8755C88EQ35572185-7F8A6BFC-7199-470C-9FC2-22B9648D2530Q36052939-034912E8-7DE9-4F8D-8D37-2EC2771836B0Q36111116-4C18C672-4141-4ADE-9102-8A1E7C95CA97Q36117205-17D2020E-45BB-4CCD-836B-C74B39502598Q36272381-195FB16E-556A-4C6E-96F1-EE12670C5E8DQ36308674-D1AB9F83-93FC-41E8-B54C-F625B8AF895CQ36469514-24D6029F-F080-4BC3-9891-87DA93E9B2D4Q36527911-C0768075-1828-4952-BFEE-13EEF32F798FQ36710908-B1A6343C-83DE-4D48-8DC6-BFEEE2BF49ADQ36986385-4E7CEFA0-5D50-44AA-93E8-7BF3F5158220Q36986412-4CE7028D-E6BA-43F6-8F77-C7645B56348EQ37026562-B52063D7-BF47-41E5-BCBA-561212D9C4AEQ37078117-182C16A3-F57E-4B0C-B65D-19D3EC98E960Q37253011-1226117B-A8CF-46BA-BE8D-58B37B9485EBQ37642390-54D1814A-5194-49AF-B766-46AC6D202F9DQ37668540-F62AEFDF-23C3-4C56-BAD3-E4C1D3903A90Q37896168-7C524066-BF61-4AB2-8FC2-2590E4D37628Q39364970-7E82548B-7B62-4A33-AB17-0C323AA95964Q39920900-E7B33BD9-7586-4B7F-904A-B92FA0841DB3Q41151931-E44D1B81-580E-4299-A379-3329FC16FB63Q41763663-35842BB1-9F04-4A23-AAB4-D7BEEEF76347Q41908271-E73C2B90-9559-4CBC-9C43-B120C53E37C8
P2860
Treating individuals 3: from subgroups to individuals: general principles and the example of carotid endarterectomy.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Treating individuals 3: from s ...... ple of carotid endarterectomy.
@ast
Treating individuals 3: from s ...... ple of carotid endarterectomy.
@en
type
label
Treating individuals 3: from s ...... ple of carotid endarterectomy.
@ast
Treating individuals 3: from s ...... ple of carotid endarterectomy.
@en
prefLabel
Treating individuals 3: from s ...... ple of carotid endarterectomy.
@ast
Treating individuals 3: from s ...... ple of carotid endarterectomy.
@en
P2093
P1433
P1476
Treating individuals 3: from s ...... ple of carotid endarterectomy.
@en
P2093
Charles P Warlow
Sally C Howard
Sergei A Gutnikov
P304
P356
10.1016/S0140-6736(05)17746-0
P407
P577
2005-01-01T00:00:00Z